Clinical Trials on Mild to Moderate TBI in Switzerland

Total 16 results

Nestlé

Completed

Psychophysiological Effects of Probiotic Supplementation

Mild to Moderate Levels of Stress

Switzerland
Cytos Biotechnology AG

Completed

Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

Mild Essential Hypertension | Moderate Essential Hypertension

Switzerland
University of Bern

Completed

Factorial Trial Investigating Outcome and Adherence Relevant Factors in an Online Self-help Intervention for Depression (HERMES)

Depression Moderate | Depression Mild

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

CLEAR Study: Clinical Experience Acquired With Raptiva Study

Moderate to Severe Psoriasis

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

Moderate to Severe Psoriasis

Switzerland
Creabilis SA

Terminated

CT 327 in the Treatment of Atopic Dermatitis

Mild to Moderate Atopic Dermatitis

Switzerland
Raphaelle Jaquet-Pilloud
Swiss Foundation for the Health of Children and Adolescents

Completed

Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3% Inhalations

Moderate to Severe Bronchiolitis

Switzerland
Wolfson Medical Center

Recruiting

Combination of Diet and Oral Budesonide for Ulcerative Colitis (ReDUCE)

Ulcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Mild

Switzerland, Israel, Italy, Netherlands
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Takeda
Zinfandel Pharmaceuticals Inc.

Terminated

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Germany, Switzerland, United Kingdom, Australia
Takeda

Terminated

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Australia, United Kingdom, Switzerland
Edwards Lifesciences
ICON plc

Terminated

Observational Registry on the HARPOON Device (REPLICATE)

Severe Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet Prolapse

Germany, Spain, Switzerland
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland

Clinical Trials on Mild to Moderate TBI in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations